Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis-Reference-Cited by-同舟云学术

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

Published:2015-05-09 Issue:1 Volume:62 Page:79-86
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Reddy K. Rajender¹,Bourlière Marc²,Sulkowski Mark³,Omata Masao⁴,Zeuzem Stefan⁵,Feld Jordan J.⁶,Lawitz Eric⁷,Marcellin Patrick⁸,Welzel Tania M.⁵,Hyland Robert⁹,Ding Xiao⁹,Yang Jenny⁹,Knox Steven⁹,Pang Phillip⁹,Dvory‐Sobol Hadas⁹,Subramanian G. Mani⁹,Symonds William⁹,McHutchison John G.⁹,Mangia Alessandra¹⁰,Gane Edward¹¹,Mizokami Masashi¹²,Pol Stanislas¹³,Afdhal Nezam¹⁴

Affiliation:

1. University of PennsylvaniaPhiladelphia PA

2. Hôpital Saint JosephMarseilles France

3. Johns Hopkins UniversityBaltimore MD

4. Yamanashi Prefectural Hospital OrganizationYamanashi Japan

5. Goethe University HospitalFrankfurt Germany

6. Sandra Rotman Center for Global HealthUniversity of TorontoToronto Ontario Canada

7. Texas Liver InstituteUniversity of Texas Health Science CenterSan Antonio TX

8. Hôpital BeaujonUniversity of ParisParis France

9. Gilead Sciences, Inc.Foster City CA

10. Liver Unit, Casa Sollievo della Sofferenza HospitalSan Giovanni Rotondo Italy

11. New Zealand Liver Transplant UnitAuckland City HospitalAuckland New Zealand